218 related articles for article (PubMed ID: 34107022)
1. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study.
Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ
Clin Infect Dis; 2021 Dec; 73(11):2037-2044. PubMed ID: 34107022
[TBL] [Abstract][Full Text] [Related]
2. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
[TBL] [Abstract][Full Text] [Related]
4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
5. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
6. Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891474
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ
J Viral Hepat; 2022 Apr; 29(4):271-279. PubMed ID: 35175671
[TBL] [Abstract][Full Text] [Related]
9. A transient positive association between direct-acting antiviral therapy for hepatitis C infection and drug-related hospitalization among people who inject drugs: Self-controlled case-series analysis of national data.
McDonald SA; Hickman M; Dillon JF; Yeung A; McAuley A; Fraser A; Hayes PC; Hutchinson SJ
Addiction; 2024 Feb; 119(2):369-378. PubMed ID: 37726951
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
11. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
[TBL] [Abstract][Full Text] [Related]
13. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
15. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
[TBL] [Abstract][Full Text] [Related]
16. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
17. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
19. Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs.
McCrary LM; Roberts KE; Bowman MC; Castillo B; Darling JM; Dunn C; Jordan R; Young JE; Schranz AJ
J Gen Intern Med; 2023 Nov; 38(15):3428-3433. PubMed ID: 37653211
[TBL] [Abstract][Full Text] [Related]
20. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
